Patients With Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors Undergoing Total Knee Arthroplasty Are at Increased Odds for a Number of Postoperative Adverse Events But Reduced Risk of Transfusion.
使用鈉-葡萄糖共轉運蛋白-2抑制劑的糖尿病患者接受全膝關節置換術後，面臨多種術後不良事件的風險增加，但輸血風險降低。
J Am Acad Orthop Surg 2024-12-04
Investigating Sodium-Glucose Cotransporter 2 Inhibitors Versus Other Glucose-Lowering Drugs on Ventricular Arrhythmias or Sudden Cardiac Death Using the US FDA Adverse Event Reporting System.
使用美國FDA不良事件報告系統調查鈉-葡萄糖共轉運蛋白2抑制劑與其他降糖藥對心室心律不整或突發性心臟死亡的影響。
Cardiovasc Drugs Ther 2024-12-04
The sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease with or without kidney transplantation - a single centre study.
慢性腎病患者（有或無腎臟移植）中鈉-葡萄糖共轉運蛋白-2 抑制劑的研究 - 單中心研究。
Bratisl Lek Listy 2024-12-04
A retrospective study of seasonal variation in sodium-glucose co-transporter 2 inhibitor-related adverse events using the Japanese adverse drug event report database.
使用日本不良藥物事件報告數據庫的鈉-葡萄糖共轉運蛋白 2 抑制劑相關不良事件季節變化的回顧性研究。
Sci Rep 2024-12-03
Effect of sodium glucose cotransporter 2 inhibitors on all cause death and rehospitalization for heart failure in patients with acute myocardial infarction.
鈉葡萄糖共轉運蛋白 2 抑制劑對急性心肌梗塞患者全因死亡及心衰再住院的影響。
Sci Rep 2024-12-03
Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial.
dapagliflozin 對非酒精性脂肪肝疾病患者肝臟脂肪變化的影響：一項隨機對照試驗。
Hepatol Int 2024-12-03
Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure.
洛卡特普和dapagliflozin聯合療法在心衰竭患者中降低尿酸水平的效果與單一療法的比較。
PeerJ 2024-12-03
Effect of optimisation to contemporary HFrEF medical therapy with sacubitril/valsartan (Entresto) and dapaglifloziN on left Ventricular reverse remodelling as demonstrated by cardiac magnetic resonance (CMR) Imaging: the ENVI study.
當代 HFrEF 醫療療法優化對左心室逆重塑的影響，使用 sacubitril/valsartan (Entresto) 和 dapagliflozin，透過心臟磁共振成像 (CMR) 展示：ENVI 研究。
Open Heart 2024-12-02